Renalytix (RENX) Price & Analysis

Compare

18 Followers

RENX Stock Chart & Stats

5.90 p

0.99 p(8.62%)

At close: Jan 09 4:00 PM EST

5.90 p

0.99 p(8.62%)

Day’s Range― - ―

52-Week Range3.00 p - 15.50 p

Previous CloseN/A

Volume11.59K

Average Volume (3M)10.03M

Market Cap

£13.77M

Enterprise Value26.40M

Total Cash (Recent Filing)£9.63M

Total Debt (Recent Filing)£8.21M

Price to Earnings (P/E)―

Beta0.01

Next Earnings

Mar 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding437,018,680

10 Day Avg. Volume3,807,103

30 Day Avg. Volume10,033,489

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)-1.38

Price to Sales (P/S)3.23

P/FCF Ratio-0.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary Diagnostic (KidneyIntelX)Renalytix's KidneyIntelX is a focused, proprietary in vitro diagnostic combining biomarkers, clinical data and machine-learning algorithms to stratify kidney risk. This differentiated product offering creates durable clinical utility and data-driven advantages that can support steady adoption and long-term commercial traction if integrated into care pathways.

Test-based Recurring Revenue ModelA fee-per-test business model ties revenue directly to clinical adoption and recurring patient testing. When sustainable reimbursement and ordering patterns exist, this model can generate predictable per-test revenue and scale efficiently, aligning incentives with providers and payors and supporting long-term commercial visibility as volumes grow.

Improving Revenue And Gross MarginRevenue growth and a material improvement in gross margin indicate improving unit economics and early operating leverage on the assay. Higher gross margins suggest the test itself has scalable economics; if volume continues to rise, these margin gains provide a credible path to narrow operating losses over the medium term.

Bears Say

Negative Shareholders' EquityNegative equity reflects cumulative losses and constrains financial flexibility. It typically necessitates external capital or restructuring to restore balance sheet health, increasing dilution or credit risk. This structural capitalization weakness is a persistent constraint until profitability or substantive recapitalization occurs.

Persistent Cash BurnMeaningful negative operating and free cash flow requires ongoing financing to fund operations. Although improved year-over-year, sustained cash burn raises refinancing and dilution risk, limits the company's ability to invest in commercialization at scale, and represents a durable funding vulnerability until cash generation turns positive.

Small Revenue Base Versus Cost StructureA very small top line combined with extremely large net losses shows the cost base far exceeds current revenue. This structural scale deficiency makes profitability highly sensitive to adoption and reimbursement gains, raising execution risk and lengthening the horizon to sustainable positive cash flow absent substantial volume expansion or cost reduction.

Renalytix News

Renalytix CEO Boosts Stake as Kidney Disease Test Rollout Advances

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix said Chief Executive James McCullough has increased his stake...

1M ago

Renalytix CFO Increases Stake as KidneyintelX.dkd Deployment Expands

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc reported that interim Chief Financial Officer Joel Jung...

1M ago

Renalytix CFO Increases Stake as Kidney Disease Test Gains Traction

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that interim Chief Financial Officer Joel Jung purchased...

1M ago

Renalytix CEO Increases Stake Amid Expansion of Kidney Disease Test

Renalytix ( ($GB:RENX) ) just unveiled an update. Renalytix plc announced that Chief Executive Officer James McCullough purchased...

1M ago

Renalytix Eyes Revenue Growth as Kidney Diagnostic Expands U.S. Footprint

The latest announcement is out from Renalytix ( ($GB:RENX) ). Renalytix reported unaudited first-half fiscal 2026 revenues of...

1M ago

Renalytix Adds Three U.S. Kidney Care Integrations and Deepens Tempus AI Collaboration

Renalytix ( ($GB:RENX) ) has shared an announcement. Renalytix has expanded the clinical footprint of its kidneyintelX.dkd test...

2M ago

Renalytix Secures Shareholder Support at AGM and Advances Kidney Disease Diagnostics

Renalytix ( ($GB:RENX) ) has provided an announcement. Renalytix announced that all resolutions were passed at its Annual...

3M ago

Renalytix Expands Kidney Disease Test Adoption and Strategic Partnerships

Renalytix ( ($GB:RENX) ) has provided an update. Renalytix has provided an update on its strategic initiatives ahead...

3M ago

Renalytix AI Reports Strong Growth and Strategic Expansion

Renalytix AI Plc ( ($RENXF) ) has released its Q4 earnings. Here is a breakdown of the information...

3M ago

Renalytix’s KidneyIntelX.dkd Test Gains Recognition for Advancing CKD Management

Renalytix ( ($GB:RENX) ) has issued an update. Renalytix announced the publication of pivotal data on its kidneyintelX.dkd...

4M ago

Three new option listings and two option delistings on October 8th

New option listings for October 8th include Amentum Holdings LLC (AMTM), RNLXY Stock (RNLXY), and VTNRQ Stock (VTNRQ)....

1y ago

AMTM

RNLX

Renalytix commences trading on OTCQB in U.S.

Renalytix announces that as previously disclosed regarding its intention to move listing of its American Depository Shares from...

1y ago

RNLX

Renalytix announces collaboration with Steno Diabetes Center

Renalytix announces a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for...

2y ago

RNLX

Renalytix announces Medicare issued coverage determination for kidneyintelX.dkd

Renalytix announces that on June 13, 2024 Medicare issued a final Local Coverage Determination, LCD, for the Company’s...

2y ago

RNLX

RENX FAQ

What was Renalytix’s price range in the past 12 months?

Renalytix lowest share price was 3.00 p and its highest was 15.50 p in the past 12 months.

What is Renalytix’s market cap?

Renalytix’s market cap is £13.77M.

When is Renalytix’s upcoming earnings report date?

Renalytix’s upcoming earnings report date is Mar 26, 2026 which is in 9 days.

How were Renalytix’s earnings last quarter?

Currently, no data Available

Is Renalytix overvalued?

According to Wall Street analysts Renalytix’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renalytix pay dividends?

Renalytix does not currently pay dividends.

What is Renalytix’s EPS estimate?

Renalytix’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renalytix have?

Renalytix has 437,018,680 shares outstanding.

What happened to Renalytix’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Renalytix?

Currently, no hedge funds are holding shares in GB:RENX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renalytix

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.